by Garth Sundem | May 21, 2019 | Featured, Latest News, Patient Care
D. Ross Camidge, MD, PhD Brigatinib is a next-generation ALK inhibitor that earned FDA approval in 2017 as a second-line therapy after treatment with crizotinib for ALK-positive non-small cell lung cancer. Recently, clinical trial results published in the New England...
by Garth Sundem | May 20, 2019 | Featured, Latest News
For a rare cancer like sarcoma, it can be difficult to find a specialist. The University of Colorado Cancer Center Multidisciplinary Clinic in Sarcoma brings together more than 20 experts to provide each patient with a personalized plan to treat their sarcoma. “Our...
by CU Cancer Center | May 14, 2019 | Members
Genomics and Microarray CoreCall for Proposals | 2019 Olink Proteomics Pilot Award Revlevant Dates:Application Deadline 5-24-2019Award Announcement ...
by Garth Sundem | May 14, 2019 | Featured, Latest News, Philanthropy
CU Cancer Center Director, Richard Schulick, MD, MBA (left), and Former Director, Paul Bunn, MD In the years since Richard Nixon signed the National Cancer Act in 1971, the overall five-year survival rate for patients diagnosed with the disease has risen from about 50...
by Garth Sundem | May 13, 2019 | Featured, Latest News, Research
Paul Norman, PhD Paul Norman, PhD, was born in the Midlands region of Central England in the county town of Shrewsbury, which, coincidentally, is also the birthplace of the naturalist and explorer, Charles Darwin. And like Darwin, Norman set out on a mission to...
